How much funding has Massive Bio raised?

Massive Bio has raised $32.1M in total funding, most recently a Series B round.

Who are Massive Bio's investors?

Massive Bio's investors include Revo Capital, DEG, Kenan Turnacioglu.

When was Massive Bio founded?

Massive Bio was founded in 2015.

Where is Massive Bio headquartered?

Massive Bio is headquartered in New York, New York, United States.

What industry is Massive Bio in?

Massive Bio operates in Healthcare.

How many employees does Massive Bio have?

Massive Bio has 51-200 employees.

Massive Bio

Empowering cancer patients globally through AI-based clinical trial matching

New York, United States · Founded 2015 · $32.1M raised

Healthcare

Headquarters: New York, New York
Employees: 51–200
Founded: 2015
Business Model: B2B2C

Website: massivebio.com
Total Funding: $32.1M
Last Round: $16.5M Series BDec 2022
Rounds: 4

About

Massive Bio is a New York-based AI-driven oncology platform that connects cancer patients and their physicians to biopharmaceutical clinical trials globally. Its SYNERGY AI engine matches patients to suitable trials based on clinical and genomic data, while its Virtual Tumor Board — comprising specialists from 25 U.S. cancer research facilities — provides personalized treatment recommendations when trial matches are unavailable. The service is always free for patients and addresses the gap whereby most U.S. cancer patients receive care in community practices rather than specialized cancer centers. Massive Bio is the official matchmaking partner for all NCI-funded clinical trials.

Summary

Massive Bio is a Healthcare company based in New York, United States, founded in 2015. It has raised $32.1M in total across 4 rounds, most recently a $16.5M Series B round in Dec 2022. Investors include Revo Capital, DEG and Kenan Turnacioglu.

LinkedIn X (Twitter)